A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial

Journal:

Nature Medicine

Published:

2026-02-28

DOI:

10.1038/s41591-026-04263-3

Affiliations:

11

Authors:

23

Go to article

Institutions	Authors	Share
Flare Therapeutics, United States of America (USA)	12.000000 12.000000	0.52
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	2.000000	0.09
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	1.000000	0.04
Sarah Cannon Research Institute (SCRI), United States of America (USA)	1.000000	0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.04
Yale Smilow Cancer Hospital, United States of America (USA)	1.000000	0.04
The START Center for Cancer Care, United States of America (USA)	1.000000	0.04
Cleveland Clinic Taussig Cancer Center, United States of America (USA)	1.000000	0.04
NEXT Oncology, United States of America (USA)	1.000000	0.04
UNC Lineberger Comprehensive Cancer Center, United States of America (USA)	1.000000	0.04
Massachusetts General Hospital (MGH), United States of America (USA)	1.000000	0.04

Interested in Oncology and Carcinogenesis?